According to WHO, there are a total of 155 new coronavirus vaccines under development worldwide, of which 23 have entered the clinical trial stage, at least 3 vaccines are currently in Phase 3 clinical trials, and at least 3 vaccines have completed phase 2 trials and are about to enter phase 3 (see the figure below for details).
Agency | Country | Progress |
Sinopharm/Wuhan Institute of Biological Products | China | Phase 3 |
Sinovac R&D | China | Phase 3 |
Oxford/AstraZeneca | UK | Phase 3 |
Sinopharm/Beijing Institute of Biological Products | China | Phase 2 |
Chinese Army's Medical Research Institute/CanSino Biologics | China | Phase 2 |
BioNTech/Pfizer | USA | Phase 2 |
Moderna | USA | Phase 2 |
A Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 2, the clinical study is expanded to several hundred persons and studies the safety, immunogenicity, recommended dosage, immunization schedule and methods of vaccination of candidate vaccinesA Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 3, the vaccine is given to thousands of people and the key goal is to evaluate the efficacy and again for safety.
The good news is all the above vaccines are now showing positive results.
The COVID-19 vaccine, as the most effective method to prevent infection with the COVID-19 virus, could be available by year end or early next year. But before getting vaccinated, keep social distancing, wear face mask and wash hands frequently can still be the best ways to protect the public from getting infected.
For government, finding (using rapid test kits) and tracking (using tracking app) could be much helpful in preventing the spread of COVID-19.
More information about Singclean IgG/IgM Test Kit, please find
-
singclean | 2020-07-29Headlining FIGO 2025: A Can’t-Miss Keynote by Prof. Osama Shawki, Presented by Singclean & KSMSingclean, in partnership with Kayan Al-Seha Medical (KSM), will debut at FIGO 2025 in Cape Town with a keynote lecture by renowned gynecologist Professor Osama Shawki. His session will spotlight innovations in hysteroscopy and adhesion prevention, showcasing Singclean’s commitment to advancing women’s healthcare worldwide.
-
singclean | 2020-07-29Singclean Draws Major Attention at ESCRS 2025 with Advanced Viscoelastic Solution for Ophthalmic SurgeryCOPENHAGEN, DENMARK – Hangzhou Singclean Medical Products Co., Ltd. made a strong impression at the 45th ESCRS Congress (European Society of Cataract and Refractive Surgeons), held September 12–16, 2025, at the Bella Center in Copenhagen. Recognized globally for its high professional standards and influence in ophthalmology, the congress gathered leading industry manufacturers, surgeons, and specialists from around the world.
-
singclean | 2020-07-29Singderm Filler Achieves 92.7% Efficacy at 12 Months in Global Clinical Trial, Validated by Landmark Thailand MasterclassBangkok, Thailand – Singderm, a globally certified dermal filler brand, has demonstrated unprecedented clinical performance in its Thailand Masterclass led by renowned physician Dr. Worawat Nolah. Three top KOLs (Hack Anantaya, Chalidaorn PinNy, Thantaya Thuranuch) received multi-zone injections with zero complications, reinforcing Singderm’s 92.7% 12-month efficacy rate from a 100-subject clinical trial.